Other I-O Approaches to Metastatic Colorectal Cancer

Video

Transcript:

Johanna C. Bendell, MD: For patients with microsatellite stable colorectal cancer, we have not really been able to see any benefit from using immunotherapies. They

Related Videos
Pashtoon Murtaza Kasi, MD, MS
Michael Iglesia, MD, PhD
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Jin Qian, PhD
A panel of 4 experts on colorectal cancer
Heinz-Josef Lenz, MD, FACP
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Michael Iglesia, MD, PhD
Kian-Huat Lim, MD, PhD
Related Content
FDA

FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC

May 16th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
John H. Strickler, MD

FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC

February 6th 2023
Podcast
Benjamin A. Weinberg, MD

Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy

May 10th 2024
Article
Jean-Yves Blay, MD, PhD, of Comprehensive Cancer Centre of Lyon

Additional 3 Years of Adjuvant Imatinib Maintenance Reduces Recurrence Risk in High-Risk GIST

May 9th 2024
Article